Ascendis Pharma Reports Strong Two-Year Data for Approved Achondroplasia Drug TransCon CNP
ASND sits 86% above its 52-week low of $124.06.
Summary
Ascendis Pharma announced positive two-year clinical trial data for its FDA-approved achondroplasia treatment, TransCon CNP, demonstrating sustained growth improvements and a favorable safety profile.
Key Events · Product Development and Regulatory · ASND
-
Positive Two-Year Trial Data
New data from the pivotal ApproaCH Trial for TransCon CNP (navepegritide) showed children maintained consistent improvements in growth through Week 104.
-
Improved Body Proportionality
Patients treated with TransCon CNP demonstrated further improvement in upper-to-lower body segment ratio during the second year of treatment.
-
Favorable Safety Profile
TransCon CNP was generally well-tolerated over two years, with most adverse events being mild or moderate and no treatment discontinuations due to adverse events.
-
Supports European Regulatory Review
This long-term efficacy and safety data strengthens the drug's profile as its Marketing Authorization Application is currently under review by the European Medicines Agency.
Analysis · ASND · Life Sciences
Ascendis Pharma's 6-K filing details positive two-year data from the pivotal ApproaCH Trial for TransCon CNP (YUVIWEL®), an already FDA-approved treatment for achondroplasia. The data reinforces the drug's long-term efficacy and safety profile, showing sustained improvements in growth and body proportionality, alongside good tolerability. This strong confirmatory data is crucial for the drug's commercial success and provides significant support for its ongoing Marketing Authorization Application review by the European Medicines Agency, with a decision anticipated in Q4 2026. While the news was released earlier today via GlobeNewswire, this 6-K serves as the official SEC disclosure, solidifying the positive clinical update.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASND was trading at $231.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.9B. The 52-week trading range was $124.06 to $248.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.